Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting

On November 7, 2022 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported the publication of abstracts reporting clinical data and a trial in progress (TIP) for Iovance tumor-infiltrating lymphocyte (TIL) cell therapies for the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting, November 8-12, 2022, in Boston, MA and virtually (Press release, Iovance Biotherapeutics, NOV 7, 2022, View Source [SID1234623250]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract reports on pooled consecutive cohorts from the C-144-01 trial with efficacy data from a total of 153 patients with advanced melanoma enrolled in Cohort 2 (n=66) and Cohort 4 (n=87). All patients had progressed on or after immune checkpoint inhibitor therapy, and targeted BRAF/MEK therapy where appropriate. Patients were heavily pre-treated (median of 3 lines of prior therapy at baseline, range: 1-9) and had substantial disease burden at baseline. As previously reported, 100% of patients received prior anti-PD-1 therapy and more than 80% of patients received prior anti-CTLA-4 therapy.

The ORR assessed by an independent review committee (IRC) using RECIST v1.1 was 31% (95% CI: 24.1%-39.4%), with 8 complete responses (CRs) and 40 partial responses (PRs). mDOR was not reached, 42% of responses extended beyond 18 months, and 40% of responses were ongoing at the median study follow-up of 27.6 months. Median overall survival (mOS) was 13.9 months (95% CI: 10.6-17.8). In patients who achieved a response at their first assessment (6 weeks after lifileucel infusion), mOS had not been reached (95% CI: 22.5 months to NR). The treatment-emergent adverse event profile was consistent with the underlying disease and known adverse event profiles of nonmyeloablative lymphodepletion and interleukin-2 (IL-2). There are no currently approved treatments for the C-144-01 study population. Available care is chemotherapy, offering 4-10% ORR and OS of 7-8 months.1-4

Friedrich Graf Finckenstein, M.D., Chief Medical Officer of Iovance, stated, "Adding to the initial positive data from our topline analysis, the analyses across pooled Cohorts 2 and 4 further demonstrate the clinical efficacy and durability of lifileucel in patients with advanced melanoma. The C-144-01 trial also validates the potential for lifileucel to become a broadly accessible TIL therapy using our centralized, scalable, 22-day manufacturing process. Our rolling BLA submission for lifileucel to the U.S. FDA is currently underway and on track to complete by the end of this year."

Additional information and patient-level detail are available in the abstract. Analyses across pooled Cohorts 2 and 4, along with key individual cohort outcomes from an updated data analysis, will be presented during a rapid oral presentation at SITC (Free SITC Whitepaper).

Investor Webcast on Thursday, November 10, 4:30 p.m. ET
Iovance will host a webcast on Thursday, November 10 at 4:30 p.m. ET to discuss clinical data updates for lifileucel in advanced melanoma. Iovance senior leadership will be joined by key opinion leaders and principal investigators in Iovance clinical studies. To participate in the webcast, please register at: View Source The live and archived webcast can be accessed in the Investors section of the company’s website at www.iovance.com.

Infinity Pharmaceuticals Announces the Date of Its Third Quarter 2022 Financial Results Conference Call and Webcast

On November 7, 2022 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, reported that it will host a conference call on Monday, November 14, 2022, at 8:30 AM ET to report its financial results for the third quarter of 2022 (Press release, Infinity Pharmaceuticals, NOV 7, 2022, View Source [SID1234623248]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the conference call, please register at https://register.vevent.com/register/BId44f86e6a2af42faadbb2844131346a8. Upon registering, each participant will be provided with call details and access codes. All participants are encouraged to join 10 minutes prior to the start time. A live webcast of the conference call can be accessed from the Events & Presentations page in the Investors/Media section of Infinity’s website at www.infi.com. An archived version of the webcast will be available on Infinity’s website for 30 days following the event.

Imunon to Hold Third Quarter 2022 Financial Results and Business Update Conference Call on Monday, November 14, 2022

On November 7, 2022 Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on DNA-mediated immunotherapy and next-generation vaccines, reported that the Company will host a conference call at 11:00 a.m. ET on Monday, November 14, 2022 to discuss financial results for the third quarter ended September 30, 2022 and provide an update on its clinical development of GEN-1, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase II clinical development for the treatment of advanced-stage ovarian cancer, and its preclinical studies of PLACCINE, a proprietary, multivalent DNA-based plasmid technology utilizing synthetic, non-viral delivery vectors, being evaluated in proof-of-concept studies for superiority over current mRNA vaccines (Press release, IMUNON, NOV 7, 2022, View Source [SID1234623247]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in the call, interested parties may dial 866-777-2509 (Toll-Free/North America) or 412-317-5413 (International/Toll) and ask for the Imunon, Inc. Third Quarter 2022 Financial Results Call. The call will also be broadcast live at www.imunon.com. The call will be archived for replay until November 28, 2022. The replay can be accessed at 877-344-7529 (U.S. Toll Free), 855-669-9658 (Canada Toll Free) or 412-317-0088 (International Toll) using replay access code 8042590. An audio replay of the call will also be available at www.imunon.com for 90 days.

Imago BioSciences to Participate in Upcoming Investor Conferences

On November 7, 2022 Imago BioSciences, Inc. ("Imago") (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, reported that Hugh Young Rienhoff, Jr., M.D., Imago’s Chief Executive Officer, will participate in two upcoming investor conferences (Press release, Imago BioSciences, NOV 7, 2022, View Source [SID1234623246]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the events are as follows:

H.C. Wainwright 3rd Annual Precision Oncology Conference. Dr. Rienhoff will present on Monday, November 14 at 12:30 pm ET.

Stifel Healthcare Conference. Dr. Rienhoff will present on Wednesday, November 16th at 8:00 am ET.

Interested parties can access the live webcasts for these conferences from the Investor Relations section of the company’s website at www.imagobio.com. The webcast replays will be available after the conclusion of each conference for approximately 90 days.

HOOKIPA Pharma to Report Third Quarter 2022 Financial Results and Corporate Updates on November 14, 2022

On November 7, 2022 HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, reported it will release its third quarter 2022 financial results and Company update before the market opens on Monday, November 14, 2022 (Press release, Hookipa Biotech, NOV 7, 2022, View Source [SID1234623245]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will not be conducting a conference call in conjunction with this earnings release.